Wender M, Tokarz-Kupczyk E, Mularek O
Katedry Neurologii AM w Poznaniu.
Neurol Neurochir Pol. 1987 Jul-Aug;21(4-5):304-8.
A group of MS patients treated with large doses of Prednisone (3960 mg over a period of 54 days with initial dose 200 mg per day) was observed during 4 years after the therapy and the results were compared with the control group treated with medium doses of Prednisone (initial dose 60 mg). The difference between two therapeutic groups estimated according to Kurtzke disability scale is statistically not significant. We cannot also conclude, that the large doses of Prednisone decrease the relapse rate. However it should be stressed that in patients treated with megadoses of Prednisone the secondary chronic progressive course of MS, more rarely developed than in cases treated with medium doses.
一组接受大剂量泼尼松治疗的多发性硬化症患者（在54天内共服用3960毫克，初始剂量为每天200毫克）在治疗后的4年里接受了观察，并将结果与接受中等剂量泼尼松治疗的对照组（初始剂量为60毫克）进行了比较。根据库尔茨克残疾量表评估，两个治疗组之间的差异在统计学上不显著。我们也不能得出大剂量泼尼松能降低复发率的结论。然而，应该强调的是，与接受中等剂量治疗的患者相比，接受大剂量泼尼松治疗的患者中，继发慢性进展型多发性硬化症的情况较少出现。
